Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course aminoglycosides as adjunctive treatment in adults with sepsis
NL-OMON29602Not yet recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2021
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, open-label trial of ceftriaxone, cefuroxime, gentamicin and tobramycin in sepsis (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: 30-day all-cause mortality. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
ceftriaxonecefuroximegentamicintobramycin
03
Conditions
sepsis
Beyond the preview
Go deeper on NL-OMON29602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29602.